T Cells Coactivated with Immobilized Anti-CD3 and Anti-CD28 as Potential Immunotherapy for Cancer

Garlie, Nina; LeFever, Ann V.; Siebenlist, Ruth E.; Levine, Bruce L.; June, Carl H.; Lum, Lawrence G.

doi:10.1097/00002371-199907000-00007

Cited by 70 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Our data suggested that CD83 signal might contribute to the long-term expansion and/or support of antigen-specific CD8 ϩ T cells. Therefore, we examined whether stimulation every 7 to 14 days with MART1 peptide-pulsed APC/A2/CD80/CD83 could induce the long-term survival of MART1-specific CD8 ϩ T cells.…”

Section: Engagement Of Cd83l Inhibits Apoptosis and Enhances Prolifermentioning

confidence: 56%

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity

Hirano

Butler

Xia

et al. 2006

Blood

150

184

View full text Add to dashboard Cite

Section: Engagement Of Cd83l Inhibits Apoptosis and Enhances Prolifermentioning

confidence: 56%

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity

Hirano

Butler

Xia

et al. 2006

Blood

150

184

View full text Add to dashboard Cite

“…The method for preparation of antibody-coated beads has been previously detailed. 29 At day 10 of culture, the expanded T cells were harvested, brought to 1 Â 10 6 cells/ml, placed into a 24-well plate, and stimulated with either unmodified MOPC tumor cells, PSA/huCD25-, or PSMAtransduced MOPC cells (each at a 10:1 T cell to tumor cell ratio), or repeat anti-CD3/anti-CD28 bead stimulation (at a 3:1 T cell to bead ratio). The 24 hour supernatants were harvested, and tested for cytokine content by commercially available two-site ELISA kits (IFN-g, IL-4, and IL-10 kits were from BioSource, Camarillo, CA; IL-2 and IL-5 kits were from R & D Systems).…”

Section: Il-2-mediated Proliferation Assay For Tranduced and Control mentioning

confidence: 99%

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

et al. 2005

View full text Add to dashboard Cite

Gene therapy for prostate cancer may be realized through transduction of whole genes, such as PSA or PSMA, into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed. Remarkably, transfer of PSA/CD25 or PSMA cDNA during murine hematopoietic cell differentiation into DCs occurred with approximately 80% efficiency. In vitro, transduced DCs retained allostimulatory function and primed syngeneic T cells for tumor antigen-specific IFN-g secretion. In test experiments designed to elucidate mechanisms in vivo, syngeneic recipients of transduced DCs had increased anti-human PSA antibody titers and tumorspecific CD8 þ T cell IFN-g secretion with no detectable immune response to CD25. Gene-modified DC recipients had increased protection from specific tumor challenge for at least 18 weeks post-vaccination. DC vaccination also protected both male and female recipients. Gene-modified DC vaccination mediated regression of established, specific gene-expressing, TRAMP-C1 prostate cancer cell tumors. These findings indicate that antibody and cellular responses generated through PSA and PSMA gene transfer into DC yielded protective immunity, thereby providing further preclinical support for the implementation of immuno-gene therapy approaches for prostate cancer.

show abstract

“…A total of 50 g of material to be labeled (CD83Ig, anti-CD83 mAb, and a mixture of anti-CD28 mAb and anti-CD3 mAb) were conjugated to magnetic beads (Tosylativated Dynabeads M-450; Dynal, Lake Success, NY) according to a published protocol (19). Beads conjugated with CD83Ig or anti-CD83 mAb were used to test the specificity of CD83Ig fusion protein.…”

Section: Labeling Of Beadsmentioning

confidence: 99%

CD83 Is a Sialic Acid-Binding Ig-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8+ T Cells

Scholler¹,

Hayden-Ledbetter

Hellström³

et al. 2001

The Journal of Immunology

View full text Add to dashboard Cite

To help determine CD83 function, a cDNA encoding a soluble protein containing the CD83 extracellular domain was fused with a mutated human IgG1 constant region (CD83Ig) and expressed by stable transfection of Chinese hamster ovary cells. Purified CD83Ig bound to peripheral blood monocytes and a subset of activated CD3+CD8+ lymphocytes but did not bind to FcR. Monocytes that had adhered to plastic lost their ability to bind to CD83Ig after 90 min of in vitro incubation. CD83Ig bound to two of five T cell lines tested, HPB-ALL and Jurkat. The binding to HPB-ALL cells significantly increased when they were grown at a low pH (pH 6.5), whereas binding to Jurkat cells increased after apoptosis was induced with anti-Fas mAb. B cell and monocytic lines did not bind CD83Ig and neither did CD56+ NK cells or granulocytes. Full-length CD83 expressed by a transfected carcinoma line mediated CD83-dependent adhesion to HPB-ALL cells. CD83Ig immunoprecipitated and immunoblotted a 72-kDa protein from HPB-ALL cells. Binding of CD83Ig to HPB-ALL cells was eliminated by neuraminidase treatment of the cells. We conclude that CD83 is an adhesion receptor with a counterreceptor expressed on monocytes and a subset of activated or stressed T lymphocytes, and that interaction between CD83 and its counterreceptor is dependent upon the state of glycosylation of a 72-kDa counterreceptor by sialic acid residues. In view of the selectivity of the expression of CD83 and its ligand, we postulate that the interaction between the two plays an important role in the induction and regulation of immune responses.

show abstract

T Cells Coactivated with Immobilized Anti-CD3 and Anti-CD28 as Potential Immunotherapy for Cancer

Cited by 70 publications

References 0 publications

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

CD83 Is a Sialic Acid-Binding Ig-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8+ T Cells

Contact Info

Product

Resources

About